Research
Hormonal
GLP-1 receptor agonists have limited efficacy in reversing advanced hepatic fibrosis compared to their ability to reduce hepatic steatosis.
If you have advanced liver scarring (fibrosis), GLP-1 medications may not reverse it, even though they will likely reduce liver fat. Newer multi-agonists (like resmetirom or dual agonists) might be needed for fibrosis.
GoodQualifiesHIGH confidence
os estudos apontam que os aGLP-1 apresentam baixa ação em estágios de fibrose... não são capazes de inibir de forma especifica a ativação de células estreladas hepáticas.
Why this rating
Based on multiple cited studies showing lack of fibrosis reversal.
Source
O EFEITO DOS ANÁLOGOS DE GLP1 NA MASLD: MECANISMOS, EVIDÊNCIAS E PERSPECTIVAS
Leonardo Lucas Prudente et al. · Revista Multidisciplinar do Nordeste Mineiro · 2025
DOI 10.61164/t9z40s73
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →